EGeen Generic Drug Development (GDD) Program
For Generic Drug Companies – Faster, Cost-Effective Clinical Bioequivalence Studies and Sales Channels
EGeen’s expertise in rapid, tailored clinical endpoint (CE) bioequivalence drug trials opens up new sales growth opportunities for generic drug developers. Utilizing EGeen’s unique Generic Drug Development (GDD) Program, generic formulation CE bioequivalence trials can be conducted in Europe on a faster, more cost effective basis. The resulting European trial data set can be used to market in both U.S. and European drug markets, leveraging the generic developers investment. And EGeen can also supply direct access to proven European sales channels to kick start your new drug’s sales growth!
Network of dedicated, skilled personnel across a host of European countries provides generic developers custom access and rapid completion of CE bioequivalence drug trials
Custom drug trial protocols combine industry-leading recruitment speed with low cost trial execution for faster trial data results
Realize your generic drug’s new formulation by accessing both EU and U.S. markets in a timely fashion for faster sales growth